initi
screen
protein
array
contain
protein
identifi
autoantigen
high
interest
show
aberrantli
high
reactiv
patient
subgroup
compar
healthi
cohort
fig
venn
diagram
fig
indic
minim
overlap
differ
retrospect
md
classif
smd
group
show
greatest
differ
compar
healthi
group
note
greater
number
avail
sampl
furthermor
consid
whole
result
support
hypothesi
md
patient
display
distinct
autoantibodi
respons
compar
healthi
cohort
see
also
supplementari
tabl
initi
screen
identifi
relev
molecular
associ
ipa
knowledg
databas
http
wwwingenuitycom
fig
includ
cancer
protein
apoptosi
viral
infect
cell
movement
supplementari
tabl
addit
protein
member
role
nfat
nuclear
factor
activ
cell
regul
immun
respons
canon
pathway
name
gnaz
two
member
thyroid
receptorretinoid
x
receptor
rtrxr
activ
pathway
trh
supplementari
tabl
supplementari
fig
highinterest
protein
stage
see
method
detail
test
valid
use
custom
protein
array
protein
success
produc
spot
fig
take
account
multipl
sourc
variabl
employ
anova
model
filter
result
elimin
effect
due
print
replic
batch
effect
subject
age
see
method
fig
identifi
protein
fig
show
aberrantli
increas
reactiv
patient
compar
healthi
p
bonferroni
correct
factor
consid
signific
confound
effect
correspond
binari
group
comparison
mean
differ
also
statist
signific
mannwhitney
utest
mean
intens
p
smd
tmd
l
versu
healthi
respect
mean
intens
p
smd
l
versu
healthi
respect
mean
intens
p
smd
tmd
l
versu
healthi
respect
classifi
differ
sampl
patient
subgroup
implement
kernel
discrimin
analysi
use
transform
intens
success
classif
retrospect
class
particularli
smd
fig
consid
smd
healthi
cohort
smd
sampl
classifi
correctli
time
standard
deviat
sd
healthi
sampl
sd
expand
classif
md
l
patient
significantli
affect
classif
smd
healthi
cohort
fig
howev
classif
lower
known
tmd
sd
l
sd
sampl
autoantibodi
reactivitybas
classif
work
less
well
classifi
sampl
known
ipss
class
fig
best
classif
intermedi
sd
classif
healthi
sampl
sd
detect
three
protein
interest
plasma
use
enzymelink
immunosorb
assay
elisa
differenti
protein
level
found
statist
signific
anova
analysi
bonferroni
correct
p
respect
fig
differenti
protein
trend
retrospect
class
reflect
autoantibodi
reactiv
post
hoc
test
bonferroni
p
display
differ
patient
group
versu
healthi
well
l
versu
tmd
differenti
protein
level
show
opposit
trend
compar
correspond
autoantibodi
reactiv
fig
post
hoc
test
bonferroni
p
display
differ
healthi
versu
tmd
smd
well
l
tmd
smd
investig
demonstr
differenti
autoantibodi
reactiv
md
patient
subset
distinct
healthi
individu
autoantibodi
display
increas
protein
reactiv
compar
healthi
patient
includ
sever
uniqu
protein
tmd
smd
l
initi
valid
stage
stage
ii
investig
find
increas
antibodi
reactiv
protein
predominantli
occur
smd
patient
consist
prior
data
indic
earli
stage
md
higher
degre
immunerel
abnorm
later
stage
protein
involv
cancerrelev
biolog
process
apoptosi
associ
involv
autoimmun
respons
differenti
reactiv
antibodi
earli
stage
md
healthi
individu
also
diagnost
util
sinc
clinic
distinct
morpholog
often
three
protein
valid
stage
ii
investig
present
robust
set
show
increas
autoantibodi
reactiv
md
patient
detect
autoantibodi
reactiv
protein
offer
possibl
new
connect
immun
respons
tumor
format
detect
particularli
note
vakt
murin
thymoma
viral
oncogen
homolog
protein
kinas
b
gamma
known
activ
involv
multipl
cancer
includ
breast
tumorigenesi
lung
ovarian
cell
cycl
involv
previou
studi
gene
overexpress
deregul
akt
pathway
detect
gene
express
addit
observ
differenti
autoantibodi
reactiv
correspond
protein
level
make
compel
case
involv
md
highlight
potenti
biomark
condit
smd
igg
receptor
involv
multipl
antibodi
process
fcreceptor
target
multipl
therapeut
approach
cancer
inflammatori
includ
genotyp
associ
rituximab
respons
protein
level
determin
elisa
show
opposit
trend
compar
correspond
autoantibodi
reactiv
protein
level
may
reflect
possibl
observ
autoantibodi
reactiv
due
nonspecif
fcreceptor
interact
rather
increas
amount
specif
antibodi
necessarili
impli
correl
amount
antigen
strength
reactiv
fact
mani
highli
express
protein
autogen
eg
albumin
neg
acutephas
protein
decreas
plasma
level
immun
small
amount
allergen
could
trigger
sever
immun
respons
adpribosyl
factorlik
involv
lysosom
traffick
posit
influenc
mtor
express
mammalian
target
rapamycin
autophagosom
may
also
associ
metastasi
patient
classif
may
made
two
separ
classif
scheme
prospect
ipss
retrospect
stl
healthi
consid
classif
scheme
show
good
overlap
ipss
low
intermedi
risk
categori
account
respect
smd
patient
total
use
autoantibodi
reactiv
classifi
patient
two
classif
scheme
retrospect
ipss
show
better
concord
autoantibodi
reactiv
stabl
patient
retrospect
classif
rather
ipss
slightli
lower
healthi
patient
classif
ipss
better
healthi
patient
suggest
combin
ipss
classif
scheme
autoantibodi
reactiv
may
improv
clinic
diagnosi
smd
patient
maintain
low
number
fals
posit
healthi
individu
furthermor
autoantibodi
reactivitybas
classif
reli
direct
molecular
marker
signatur
may
possibl
applic
altern
supplement
ipss
risk
estim
especi
earli
detect
smd
patient
final
detect
autoantibodi
reactiv
would
requir
plasma
minim
invas
patient
studi
discov
differenti
autoantibodi
reactiv
md
identifi
autoantibodi
particular
prognost
md
subset
demonstr
protein
microarray
provid
power
approach
identifi
uniqu
biomark
associ
diseas
investig
chose
sensit
focus
protein
array
approach
tradit
chromogen
elisa
valid
purpos
envis
highthroughput
fluorescencebas
method
protein
microarray
may
eventu
replac
tradit
chromogen
elisa
clinic
test
expect
elisa
clinic
test
may
also
develop
futur
base
find
regard
possibl
specif
find
although
autoantibodi
studi
yet
report
hematolog
malign
combin
autoantibodi
reactiv
observ
md
patient
distinct
report
patient
cancer
respiratori
expect
find
increas
autoantibodi
reactiv
md
patient
rel
prolong
clinic
cours
encourag
futur
studi
larger
patient
cohort
help
substanti
prognost
import
data
explor
underli
molecular
mechan
identifi
autoantibodi
reactiv
may
greatli
enhanc
diagnost
prognost
capabl
md
patient
recruit
plasma
sampl
collect
carri
stanford
univers
medic
center
inform
consent
approv
stanford
intern
review
board
human
subject
plasma
sampl
randomli
obtain
group
md
patient
seen
longterm
followup
avail
sampl
obtain
either
time
md
diagnosi
diseas
cours
median
month
diagnosi
rang
mean
sem
month
stage
autoantibodi
reactiv
profil
retrospect
patient
subset
tabl
use
invitrogen
protoarray
protein
microarray
uniqu
human
protein
spot
duplic
signal
total
includ
control
describ
parallel
duplic
neg
control
array
probe
plasma
sampl
dilut
ml
wash
buffer
pb
tween
rotiblock
protoarray
dri
scan
use
genepix
microarray
scanner
molecular
devic
sunnyval
ca
obtain
array
imag
analyz
genepix
pro
molecular
devic
obtain
featur
locat
signal
foreground
background
intens
quantif
correspond
identif
inform
gpr
file
format
addit
probe
igg
reactiv
nm
channel
array
spot
protein
contain
glutathion
stransferas
gst
fusion
tag
second
channel
nm
screen
allow
us
probe
gst
intens
use
proxi
protein
concentr
per
array
spot
see
also
supplementari
fig
stage
ii
custom
protein
array
creat
probe
autoantibodi
reactiv
enlarg
cohort
tabl
figur
array
produc
invitrogen
use
protoarray
technolog
figur
compris
block
duplic
protein
spot
total
per
block
protein
stage
use
analyz
protein
reactiv
one
subject
sampl
per
block
includ
differenti
react
protein
interest
identifi
stage
randomli
select
control
protein
probe
procedur
carri
stage
describ
includ
neg
control
array
imag
analyz
stage
obtain
signal
inform
block
consid
separ
includ
probe
gst
intens
array
analyz
multistep
process
involv
inter
intraarray
normal
signal
comparison
group
identifi
initi
highinterest
protein
set
display
increas
igg
reactiv
patient
subgroup
fig
array
per
channel
intraarray
normal
perform
via
implement
procat
slide
window
paramet
length
take
account
local
background
subtract
local
intens
normal
across
array
local
intens
adjust
necessari
correct
array
variat
stem
print
probe
procedur
adjust
probe
scan
procedur
variat
interarray
intens
quantil
probe
intens
compar
binari
comparison
patient
retrospect
healthi
group
procedur
previous
shown
highli
reproduc
technic
replic
duplic
studi
compar
differ
patient
subgroup
one
anoth
specif
interest
signal
show
increas
reactiv
retrospect
analyz
md
patient
versu
healthi
control
group
particularli
smd
assess
statist
signific
twotail
mannwhitney
test
mathematica
multipl
hypothes
bonferroni
adjust
p
filter
control
signal
protein
spot
inconsist
print
array
ie
display
differenti
gsttag
signal
due
variabl
array
print
total
protein
show
increas
reactiv
cutoff
p
bonferroni
adjust
p
identifi
highinterest
protein
comparison
md
subset
healthi
cohort
fig
use
pathway
function
analysi
ipa
system
http
wwwingenuitycom
identifi
relev
biolog
function
ingenu
knowledg
base
fig
determin
probabl
biolog
function
assign
data
set
due
chanc
alon
p
valu
calcul
use
righttail
fisher
exact
test
p
addit
canon
pathway
ipa
librari
statist
signific
ascertain
base
pvalu
p
fisher
exact
test
ratio
molecul
data
set
compar
total
network
see
also
supplementari
inform
subsequ
valid
stage
studi
success
express
protein
onto
custom
focus
array
describ
note
protein
initi
list
candid
includ
valid
could
either
success
express
isol
print
lack
proper
clone
low
viabil
specif
clone
low
yield
isol
print
error
etc
pass
strict
secondari
qualiti
control
select
focus
array
print
ad
measur
valid
reproduc
larg
gstsignal
variat
neg
flag
rais
scan
satur
signal
nonreproduc
varianc
stabil
signal
analysi
addit
studi
expand
much
larger
cohort
tabl
protein
array
scan
describ
block
correspond
differ
patient
patient
sampl
perform
duplic
use
inter
intraarray
normal
stage
fig
appli
per
block
signal
protein
spot
transform
normal
distribut
use
boxcox
protein
analyz
use
anova
check
varianc
subject
subgroup
retrospect
classif
replic
duplic
sampl
duplic
protein
spot
subject
age
gender
marrow
blast
level
healthi
ipss
blast
categori
leukem
statu
random
effect
batch
effect
stage
ii
investig
fig
possibl
interact
also
consid
signal
show
signific
primari
effect
signific
interact
use
bonferroni
posthoc
test
correct
multipl
group
featur
comparison
select
signal
interest
addit
anova
use
screen
signal
show
signific
effect
due
replic
subject
age
random
furthermor
ensur
protein
level
vari
array
statist
signific
differenti
gst
signal
elimin
base
anova
standard
transform
reactiv
level
found
higher
patient
versu
healthi
cohort
fig
protein
use
classif
name
kda
packag
use
unconstrain
smooth
crossvalid
method
bandwidth
select
linear
discrimin
analysi
lda
packag
see
supplementari
tabl
kda
outperform
lda
retrospect
ipss
classif
method
involv
assign
class
crossvalid
perform
random
data
partit
fig
util
elisa
kit
measur
plasma
level
dilut
catalog
cell
signal
dilut
catalog
uscn
life
scienc
inc
dilut
mybiosourc
catalog
use
sampl
subject
total
smd
tmd
l
healthi
subject
test
triplic
follow
manufactur
instruct
fig
gim
rc
contribut
equal
project
conceiv
studi
project
plan
experiment
design
work
statist
analysi
wrote
manuscript
yz
ks
ds
hi
involv
experiment
work
manuscript
edit
lx
involv
financ
supervis
yz
manuscript
edit
plg
mp
supervis
project
involv
project
plan
financ
supervis
manuscript
prepar
plg
mp
senior
author
access
code
protein
array
data
custom
array
design
submit
gene
express
omnibu
geo
repositori
access
respect
